ASX ANNOUNCEMENT **2 OCTOBER 2025**

CHM CORE-NK PHASE 1B CLINICAL TRIAL ACHIEVES ADDITONAL COMPLETE RESPONSES IN AML

- **Clinical and translational data on the Dose Escalation phase was presented at the Society of Hematology Oncology Annual Meeting in Houston, Texas**
- **To date, fifty seven percent (57%) of the evaluable high-risk frontline subjects treated with this novel combination have demonstrated clinical responses**
- **Two new Complete Responses in AML, in addition to the two previously reported[1]**

Sydney, Australia, 2 October 2025: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce new clinical and translational data from the ADVENT-AML clinical trial that was presented at the Society of Hematology Oncology Annual Meeting in Houston, Texas.

The poster presentation focuses on the Dose Escalation portion of the ADVENT-AML trial, treating patients with relapsed or refractory AML.

The Dose Escalation portion of the trial evaluated the safety of two CORE-NK doses in combination with standard AML treatment, and was completed in late 2024. Six study subjects with relapsed or refractory AML were treated at one of the two dose levels. Patients' ages ranged from 35-77 years and had received 2-4 prior lines of AML therapy. There were no dose-limiting toxicities, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity (ICANS), or graft verses host disease (GVHD). CORE-NK cells persisted in patients blood for more than two weeks after repeat infusions. One patient achieved a complete response.

In addition to the six patients treated in the dose escalation phase, we are pleased to announce that seven evaluable subjects have been treated in the ongoing frontline cohort of high-risk patients with newly diagnosed AML. The frontline cohort is enrolling patients at The University of Texas MD Anderson Cancer Center and Case Western Reserve University. In this actively enrolling cohort, four clinical responses have been reported which include two complete responses (CRs) one complete response with incomplete count recovery (CRi) and one partial response (PR). There have been no unexpected safety findings in this group of patients and the combination of CORE-NK with azacitadine and venetoclax continues to be well-tolerated by patients.

"We are very happy to support this work that now provides scientific validation for this novel clinical combination. We eagerly anticipate the potentially practice-changing results from the ongoing dose expansion phase in newly diagnosed elderly or infirmed AML patients." said Jason B Litten MD, CMO of Chimeric Therapeutics.

The ADVENT-AML (NCT05834244) Phase 1B clinical trial is an investigator-initiated study currently open to enrollment at MD Anderson Cancer Center under Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia. The study is evaluating the synergy of NK cell therapy in combination with the current standard of care, azacitidine and venetoclax. ADVENT-AML is the first clinical trial to evaluate the synergy of CORE-NK in combination with the current standard of care for AML patients.

Since the combination has demonstrated safety in subjects with relapsed or refractory disease, the study is now open to enroll up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant.

The CORE-NK cells used in the ADVENT-AML clinical trial were manufactured and cryopreserved for "off-the-shelf" accessibility at the Cellular Therapy Integrated Services Laboratory at Case Western Reserve University, where the CHM 0201 cells were developed.

[1] https://app.sharelinktechnologies.com/announcement/asx/df856b9e51b450a76df8ad96f53345db

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer.
To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in March 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase

1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper

Contact
Investors
Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au